The Course of Acute Respiratory Failure in Geriatric Patients With Hip Fracture Using Different Modes of a Vibroacoustic Device for the Lungs
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Vibrolung.
- Who it may be relevant to
- Registry conditions: Vibration, Respiratory Complications. Basic parameters: 60 years — 85 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Kazakhstan
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
A medical professional trained in the procedure and use of the device will conduct the vibroacoustic therapy session. He will also take blood samples. In the control group, patients will undergo vibroacoustic pulmonary therapy in the "Pneumonia" mode, and in the control group, in the "Prevention" mode. Vibroacoustic pulmonary therapy will be conducted over a period of 5 days. A similar algorithm of actions is planned for both groups. VALT sessions will be conducted 4-6 times a day for 5 minutes in combination with treatment according to the protocol for the use of "Vibroacoustic Therapy" of the lungs of the Ministry of Health of the Republic of Kazakhstan. The device's emitters will be applied to the affected areas of the lungs. Since the device has long cords for the emitters and is portable, it is not difficult to change the patient's position and does not require their active participation, which is important for patients on ventilators and with limited mobility.
Interventions
- Device Vibrolung
BARK VibroLUNG vibroacoustic device (No. RK-MT-7No.013611 dated October 7, 2014). The device is designed for the treatment and prevention of respiratory diseases. The device operates on the principle of exposure to a powerful vibroacoustic signal generated by special emitters. During the procedure, the emitters are pressed against the surface of the chest, and the procedure lasts an average of 5 minutes. The frequency of the signal constantly changes and has complex modulation, which ensures max
Primary outcome measures
- Arterial blood gases [Time frame: Day 1]
Secondary outcome measures (1)
- Chest X-ray [Time frame: Day 1]
Eligibility criteria
- respiratory failure;
- hip fracture;
- Injury Severity Score no higher than 8 points.
Exclusion criteria
- All contraindications for use of the device:
- terminal condition of the patient;
- shock;
- paradoxical pathological breathing;
- hypertensive crisis;
- severe hypocoagulation with a risk of hematoma formation or bleeding in the projection of exposure;
- severe hypercoagulation, risk of thrombus/embolus migration along the main vessels in the area of exposure;
- acute cerebrovascular accident in the first 1-3 days;
- brain edema;
- presence of multiple purulent or burn wound surfaces in the area of exposure;
- presence of unstable rib fractures;
- pneumomediastinum and/or subcutaneous emphysema of the chest;
- osteomyelitis of the ribs and/or thoracic spine;
- spinal fracture without orthopedic fixation;
- chest or abdominal trauma with bleeding;
- Injury Severity Score greater than 8 points;
- concomitant diseases in the stage of decompensation.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Single blind
- Primary purpose
- Basic science
Study locations
Kazakhstan · 1 center
- Astana medical university — Astana
Identifiers
NCT: NCT07517497 · AP25795127 · Grant No.AP25795127